Hanover has been hired by UCB to help attract UK life science investment to the Belgium biopharma company.
The London-based agency has been handed a public affairs and corporate comms brief to raise UCB’s profile within the UK’s £50bn life science sector.
“UCB is one of the top five life science research and development investors in the UK and has a huge amount to offer patients, the NHS and this country’s economic growth agenda,” said Andrew Harrison, head of healthcare at Hanover.
Harrison will lead the two-year, six-figure account, reporting to UCB’s director of government affairs Gordon Lundie and head of UK comms Scott Fleming.
Commenting on the agreement, Lundie said: “Throughout the pitch process the team showed a real passion and enthusiasm for our work and their health expertise in both London and Brussels gave them a competitive advantage.”